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Allogenic hematopoietic progenitor cell transplantation (allo-HSCT) is an established treatment for many diseases. Stem cells may
be obtained from different sources: mobilized peripheral blood stem cells, bone marrow, and umbilical cord blood. The progress in
transplantation procedures, the establishment of experienced transplant centres, and the creation of unrelated adult donor registries
and cord blood banks gave those without an human leucocyte antigen- (HLA-) identical sibling donor the opportunity to find a
donor and cord blood units worldwide. HSCT imposes operative cautions so that the entire donation/transplantation procedure
is safe for both donors and recipients; it carries with it significant clinical, moral, and ethical concerns, mostly when donors are
minors. The following points have been stressed: the donation should be excluded when excessive risks for the donor are
reasonable, donors must receive an accurate information regarding eventual adverse events and health burden for the donors
themselves, a valid consent is required, and the recipient’s risks must be outweighed by the expected benefits. The issue of
conflict of interest, when the same physician has the responsibility for both donor selection and recipient care, is highlighted as
well as the need of an adequate insurance protection for all the parties involved.
1. Introduction
Allogenic hematopoietic progenitor cell transplantation
(allo-HSCT) is an established therapeutic strategy for many
hematologic malignancies, bone marrow failure syndromes,
and metabolic diseases [1]. In allo-HSCT, a relatively small
inoculum of donor hematopoietic cells is called upon to reca-
pitulate a diverse and fully functional hematopoietic system
in the recipient [2].
Stem cells for HSCT may be obtained from different
sources: mobilized peripheral blood stem cells (PBSCs), bone
marrow (BM), and umbilical cord blood (UCB) [3].
The progress in transplantation procedures, the estab-
lishment of experienced transplant centres, and the creation
of unrelated adult donor registries and cord blood banks gave
those without an HLA-identical sibling donor the opportu-
nity of a concrete hope to find a donor and cord blood units
worldwide [4].
Overall, the donation of organs and tissues represents a
fundamental resource for all humanity, an example of altru-
ism with the aim of helping sick people in need. If we tend to
relate to the beneficial effect of donation, we can say that dona-
tion may represent a sort of ethical duty for all people; on the
other hand, health institutions have a perfectly symmetrical
duty to guarantee safety for donors. Careful selection of poten-
tial donors, clinical evaluation and management of the entire
donation/transplantation procedure by experts, and a proper
communicative process represent the key points of HSCT [5].
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The transplantation procedure is complex both from a
clinical and from an ethical point of view. Ethical and clinical
concerns related to the different phases of the process (pre-
transplantation care, donor search, harvest, transplantation
phase, and short and long-term follow-up) are likely to over-
lap and intersect each other [6].
2. The Beginning
After the detonation of nuclear weapons in the SecondWorld
War, there was a surge in knowledge of the biology of hema-
topoiesis and the possible use of HSCT as a rescue strategy
for radiation-induced bone marrow injury [7].
The first studies performed in mice led to remarkable
results in hematopoiesis and suggested insights regarding
potential clinical use. The first steps toward understanding
the mechanisms of hematopoietic stem arise from the obser-
vation made by Jacobson and colleagues that in mice treated
with lethal irradiation, the spleen protection allowed the
conservation of hematopoiesis [8]. Is due to Lorenz et al. the
first evidence about the infusion of bone marrow in mice, as
hemopoietic recovery after radiation injury [9]. In 1957,
Thomas and colleagues lead the first experiment on human
beings, with the treatment of acute leukaemia with a bone
marrow infusion from fetal and adult cadavers [10]; impor-
tantly, the authors reported the observation of an immunolog-
ical reactionmediated by the graft against the leukaemia cells.
For several years, the research on murine and canine
models fed the comprehension that transplantation of bone
marrow leads to hematopoietic recovery after injury, both
heterologous and autologous infusion [11, 12] and that the
infusion is related to immune reaction mediated by genetic
factors, nowadays known as graft-versus-host disease
(GVHD) [13, 14].
The subsequent steps of those studies led to an under-
standing of the crucial role of the histocompatibility anti-
gens, up to the discovery of the human leukocyte antigen
(HLA) that codes for the major histocompatibility com-
plex (MHC) [15–19].
In the early seventies, thefirst allogenic transplants of bone
marrowwere limited to congenital and acquired bonemarrow
failure syndromes, immunodeficiencies, and advanced refrac-
tory leukaemia [20–22]. By 1980, the curative potential of
HSCTs had encouraged its use in malignancies previously
considered “incurable,” such as chronic myelogenous leukae-
mia. Allo-HSCT was also increasingly utilized as a curative
therapy not only for severe aplastic anaemia but also for other
severe nonmalignant conditions, such as thalassemia, sickle
cell anaemia, and inborn metabolism errors as well [7].
A historical step in the strategy of HSCTs has been the
collection of a stem cell product through venous access rather
than through a bone marrow harvest. The discovery of the
physiological presence of CD34 hematopoietic stem cells in
the peripheral blood and the administration of mobilizing
cytokines allows the greater expansion of the number of stem
cells [23–26].
In 1989, Gianni et al. utilized the granulocyte colony-
stimulating factor (G-CSF) to mobilize bone marrow stem
cells into the peripheral blood, thus favouring the collection
of peripheral blood stem cells [27], used both for autologous
and for allo-HSCT [28].
The choice of bone marrow or peripheral blood as source
for allogeneic transplantation in adults is still under study
and evaluation [29].
In 1988, for the first time, a HLA-matched sibling
successfully donated cord blood-derived stem cells to a
patient affected by Fanconi anaemia [30].
3. The Clinical Challenge
Historically, HLA-matched donors are the most suitable for
allo-HSCT. However, progress in studies allows to state that
it is not necessary [31].
This is especially true when it is considered the significant
expansion of the donors thanks to the introduction of the
Reduced Intensity Regimens [22].
The Reduced Intensity Regimens was developed over a
period of several years. Santos and colleagues introduced a
combination of busulfan and cyclophosphamide [32],
followed by several methods of reduced conditioning regi-
mens available in human transplants [33].
The reduced regimen often produces mixed repertoire
from both donor and recipient cells that after transplant, it
turns in a conversion to a donor-derived hematopoietic cell
and T-cell population. These approaches overcome the his-
torical problem of age limit for HSCT [7]. However, relapse
is still a critical point in these cases and myeloablative condi-
tioning remains standard in younger patients with rapidly
proliferating malignancies [34]. It has been reported that
some ethnic groups have an increased susceptibility to the
immune-mediated adverse drug reactions (ADRs), a phe-
nomenon related to HLA allele frequency [35].
The possibility of allo-HSCT from unrelated donors is
definitely the result of the increased knowledge of the
HLA system and the improved HLA typing techniques.
The registries of unrelated donors show a remarkable
ethnical variability, for example, the odds of finding a full
match for a Caucasian patient is approximately 70%,
whereas this number is 18% for African Americans. One
or two antigen-mismatched transplants have been carried
out in this situation, but the incidence of graft failure
and GVHD remains problematic [7]. Every HLA antigen
mismatch between the donor and the recipient has been
shown to adversely affect the success of allogeneic trans-
plant [36].
The donor age does not appear as a limit for the allo-
HSCT. It is proved that it does not determine the risk of
prolonged neutropenia or thrombocytopenia of delayed
engraftment and graft rejection and of development of
malignant clonal disorder. Furthermore, no major long-
term adverse effects on GVHD and 5-year nonrelapse
mortality have been seen with grafts from older donors.
It is noticed also that the transplant from older sibling
donors is associated with lower risk of acute GVHD
grades II to IV compared with younger donors [2].
Cord blood and partially HLA-matched related (haploi-
dentical) donors represent a new approach for allo-HSCT that
overcomeHLA barriers and the related limit due to high rates
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of graft rejection and GVHD. These modern approaches to
donor selection mean that for any patient who need trans-
plant, there is a possible donor. Anyway, the critical problems
related to transplant procedures, such as risk of GVHD,
relapses, infectious complications, remain a challenge to
overcome.
UCB transplantation is suitable also when MHC-mis-
matched donors are enrolled, because the risk of GVHD is
lower than other transplantations [37]. The T-cell repertoire
is entirely established at birth, as well as the CB B-cell reper-
toire [38–41]. The clonal predominance in complex T-cell
populations (polyclonal versus oligoclonal or monoclonal
profiles), detected by the analysis of complementary-
determining regions (CDR) length, is the major difference
between the adult and the CB T-cell repertoire. The absence
of antigenic exposure can be related to the peculiar
polyclonal profiles observed in CB T-cell. This condition
could explain the lower rate of GVHD reported after CB
transplantation [42].
4. Donor Selection
In BM donation, drug administration is not required. Hemo-
poietic stem cells are aspirated from the hips, which requires
general or regional anaesthesia and a brief hospitalization for
the donor [4, 43]. The main risks are those related to anaes-
thesia, but postdonation deaths have been described, due to
cardiorespiratory arrest, pulmonary embolism, sickle cell
crisis, and stroke [44]. Although the incidence of severe and
fatal adverse events is very rare [4], severe blood loss, wound
infection, and pain at the site of puncture have been
reported as potential morbidity risks [45]. Fatigue, low
back pain, headaches, nausea, walking difficulties, and
sleep disorders represent the most frequent short-term
negative events related to bone marrow donation. Rarely,
long-term adverse effects may occur, such as chronic pain
at the donation site and the need of iron supplementation
and, even, of blood transfusion in smaller children who
donate for larger recipients [46–49].
The repeated injections of G-CSF in periferal blood
(PB) transplantation may be associated with bone pain.
Overall, due to the procedure of PB donation, risks of het-
erologous blood products, thrombocytopenia, and spleen
rupture have been described [50–52].
In 2001, theWorldMarrowDonor Association (WMDA)
established a reporting registry for serious adverse events due
to stem cell donation by unrelated donors [4]. The most fre-
quent adverse events in BM donation were cardiac arrest
and those related to anaesthesia [53]. BM donors most often
reported pain at the collection site and anaesthesia site;
fatigue was the frequently reported symptom [54].
Six serious adverse reactions (as defined by the WMDA)
were reported in those donors making a subsequent dona-
tion (either for the same patient or a different patient,
n = 107), a rate of 5.6%. Although this rate of serious
adverse reactions differed statistically from that in first-
time donors (RR = 3 29, P = 0 005), overall numbers were
small [55].
Over the time, the WMDA has guaranteed uniformity,
quality, and safety of unrelated donations (UDs); on the con-
trary, critical questions remain for related donors (RDs). Sit-
uation of conflicts of interest (a member of the medical team
engaged in both donation and transplantation), the lack of
standardized clinical eligibility criteria and of centralization
of adverse event, and donor follow-up reporting system are
challenging points [56].
In 2010, the Ethics Working Group and the Clinical
Working Group of the WMDA issued recommendations
for family donor care [57]. In 2013, the Worldwide Network
for Blood and Marrow Transplantation (WBMT) issued a
consensus statement on the standardization of the assess-
ment of donor outcome [58].
Some evidence from the literature suggest that hemato-
poietic progenitor cell (HPC) donation is safer for UDs than
RDs. Halter et al. reported the early death (<30 days) of five
related donors in 36,317 family donations between 1993
and 2005 while no deaths were reported in 14,706 donations
from volunteer UDs [53].
Other authors reported similar findings [59], mostly
focusing on the lack of adherence to the clinical eligibility cri-
teria [60, 61].
An Italian survey reported that only 26.4% donors under-
went thorough screening in accordance with Italian Bone
Marrow Donor Registry standards [62].
Standard certified criteria and terms for medical suitabil-
ity of RDs should be guaranteed [57].
In family donations, psychological as well as physical
well-being has to be specifically addressed. Apart from phys-
ical, clinical effects and consequences of the donation proce-
dure and psychological impact of donation may be
significant both in positive and in negative sense. Undoubt-
edly, the act of donation can be experienced in a positive
way by the donor; in the case of negative outcome of the
transplant, psychological difficulties may arise for the donor,
particularly if his/her recipient dies or develops severe
adverse events [63, 64].
The need of a strict donor follow-up has been recently
highlighted, focusing on the reporting of any serious
adverse reaction occurring early (<30 days) after the dona-
tion procedure. Furthermore, a long-term follow-up of
HPC donors is desirable once every one-two years for at
least 10 years [58, 65, 66].
The issue of safety is reported as critical with particular
attention to the comparison between allogeneic BM and
PBSC donations [67]. Both BM and PB donation procedures
may be burdened by the same psychologic effects, fatigue,
and reduced energy after the procedure. More severe pain
at the donation site, greater incidence of hemorrhage, anae-
mia, and hypotension, and a tendency to have more days of
restricted activity and hospitalization may occur related to
BM donation. Even if a greater number of adverse events in
the BM group (56%) compared with those in the PB group
(44%) are reported, there is no clear evidence of which collec-
tion method is safer for the donor [46, 67–71].
UCB has been used successfully since 1988 as a source
of hematopoietic stem cells for transplantation involving
sibling donors and, more recently, unrelated recipients
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[72, 73]. UCB donation may represent a less critical proce-
dure from the point of view of HLA matching, because
lymphocytes in cord blood have a minor immunological
reactivity than lymphocytes from older donors [74].
Due to the widespread use of UCB donation, public cord
blood banking becomes a reality, where units donated by
anybody can be used by anybody else [73]. Scientific societies
made a strong case for public cord blood banking, and
national and international efforts aimed at expanding collec-
tion and storage [75–77], as when the number of units stored
in public banks increases, the chances of finding a matching
unit also increase.
Public cord banks coexist with private cord blood regis-
tries that counsel the storage of a newborn infant’s cord
blood in the unlikely event that siblings suffer from a disease
necessitating a transplant [78]. The chances of self-use when
stored in private banks are slim [79]. In general, public
banking is favoured by the American Academy of Pediatrics,
the American Medical Association, the American College of
Obstetrics and Gynaecology, and the American Society for
Blood and Marrow Transplantation [80–82].
Unrelated UCB is an alternative source of allo-HSCT
with a less stringent need to match HLA types as compared
with harvesting HSC from bone marrow or nonneonatal
peripheral blood. However, failure to restore hematopoiesis
after allogeneic UCB transplantation due to HLA-specific
antibodies in the recipient and the small number of cells
from UCB undermines the potential for therapeutic
success [83–85].
5. The Issue of Children
Children may be a source of hematopoietic stem cell most
commonly in the case of children requiring transplant.
Potentially, children may also donate for adults (sibling,
parent, or other family members) [86, 87].
Two thousand allo-HSCT are performed annually in
children in the USA, many on research protocols. For
approximately one-third, the HSC donor is also a child, typ-
ically a healthy sibling who undergoes bone marrow harvest
or large volume apheresis for collection of peripheral blood
stem cells [1].
Because donation of HC does not improve the donor’s
own physical health and carries a risk of side effects, careful
assessment of medical risks specific to the individual donor
must be considered, as well as the ethical and legal aspects
associated with donation from a child [88].
Generally, the risks related to donation by minors
are modest and rarely severe adverse events are reported
[46, 51, 89]. Particularly in the paediatric donor population,
a long-term follow-up is substantial and it is even more
necessary if children are treated with G-CSF. There is no
direct medical benefit from serving as a stem cell donor.
The benefit is always stated as the psychosocial benefit of
helping a sibling or other close family members. However,
the donation procedure may carry medical risks, mostly
related to anaesthesia and more rarely to nerve, bone, or
tissue injury [47, 90–92].
From an ethical point of view, the central knot in stem
cell donation by a minor is carefully considering and balan-
cing the risks and benefits of the potential donor and, on
the other hand, the contextual perils and advantages to the
recipient and to his or her family [93, 94].
Recognizing that HSC donors face risks without the
potential for direct medical benefit, the American Academy
of Pediatrics (AAP) recently published guidelines specifying
when minors may ethically serve as HSC donors for a
standard (nonresearch) transplant [51, 92, 95]. In the
2011 statement of AAP, five criteria were proposed to be
fulfilled so that the donation by a minor could be ethically
acceptable [86].
The absence of a medically equivalent histocompatible
adult relative suitable for donation is the first imperative
criterion. Within this conceptual paradigm, several subse-
quent steps are to be followed. In the case of multiple histo-
compatible, clinically equivalent siblings, the age of the
potential donor above or closest to that of consent represents
a priority criterion. The AAP statement takes note of the
complexity of a parental decision-making process in stem cell
donation by a minor and of the difficulties of the eventual
sequential search for an unrelated donor through the inter-
national registries that may be time consuming, frustrating,
unsuccessful, and very expensive [93]. Therefore, the simul-
taneous, not sequential, search of stem cell research from
all the potential sources appears ethically acceptable. Sec-
ondly, the AAP underlines the ethical and moral problematic
nature of asking a minor to donate for an unknown, emo-
tionally distant relative. Consequently, it is opportune that
an interpersonal healthy relationship between the donor
and the recipient exists. Donation for strangers from minors
and their enrollment in international registries are unaccept-
able except for cord blood donations.
The likelihood that the recipient will benefit from trans-
plantation represents the third criterion. The donor’s psy-
chosocial burden of a disastrous transplant has to be
carefully weighted when a donation by a minor is taken into
consideration [96], particularly when the potential recipient
is a sibling.
This issue is strictly intertwined with the fourth condition
that reinforces the need of a careful balance between the
overall risks to the donor and the benefits expected both to
the donor and to the recipient. In the light of this criterion,
the proper selection of the method of stem cells collection
is pivotal. It is noteworthy that the inclusion of the potential
child donors in the decision-making process and other strat-
egies as medical play acting may be useful in minimizing
psychological and emotional burden related to the donation
procedure [97–101].
Finally, it is mandatory that parental permission and
donor assent are obtained.
Conclusively, medical criteria for donor selection, inde-
pendent assessment, and a donor follow-up are substantial
in the paediatric setting as in the adult one. Some peculiar
issues related to the paediatric population, such as the role
of the minors in parental decisional process, and the relation-
ship between the donor and the potential recipients within
the familial context deserve particular attention [47, 90].
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6. Informed Consent: How Much Information?
The legal and ethical framework within which we are moving
is the assumption that the human subject’s voluntary consent
to any kind of medical treatment is absolutely essential. This
means that the person involved should have the capacity to
give consent, should be in such a position as to be able to
exercise free power of informed choice, without any form of
constraint or coercion, and should have enough knowledge
and comprehension of the issue involved in his/her condition
as to enable him/her to make an understanding and enlight-
ened decision. For decision makers to make an informed
choice, especially about tissue, organ, and blood donation,
they must have a firm understanding of the processes, risks,
and benefits associated with donation.
Several elements should be considered critical with
regard to informed consent to tissue and blood donation.
The first of these is the conceptual paradigm that in stem cells
donation, regardless of the sources and as in all types of
donation, there is no medical benefit to the donor. Every kind
of donation is of vital interest to society as a whole. However,
the traditional physician-patient relationship is affected by
the fact that the patient is the subject of donation rather than
the subject of treatment. Donation does not purport to bene-
fit the subject; instead, the subject helps the potential recipi-
ent of his/her donation. Donors consent to the “invasion”
of their person or to procedures, the results of which are of
potential benefit to others (the recipients). Thus, the diffi-
culty of quantitatively and qualitatively measuring the extent
of the risks related to donation has to be counterbalanced
with the measurement of the benefits for future, potential
recipients. Accepting this concept requires acceptance of
the subsequent concept that it is necessary to balance the
potential benefit to the recipients with the potential risks to
the donors. The degree of risks for the donor should never
be excessive. When this balance between risks and benefits
is achievable, the following step is the respect for the donor’s
autonomy, as realized through their informed consent.
In this regard, a fundamental issue is the amount of infor-
mation which is to be provided to the donor. How much is to
be told about the donation procedure and how should it be
told? What risks of donation should be explained? Are some
risks to be concealed from the patient?
Different types of HSC sources imply different types of
risks related to donation. The ways in which HSC are
obtained, as well as the way and type of information provided
to donors about benefits and risks, is likely to influence a
person’s willingness to donate. While there is no doubt that
the donor’s voluntary and informed consent is the ethical
and legal prerequisite for donation, it may be debatable, from
an ethical point of view, how much information is adequate
and how much choice donors should have.
One of the major ethical issue in the context of donation
is therefore the amount of the information. In fact, if consent
must be informed, it is fundamental that the information
should be truthful and complete. But, in this peculiar context,
the problematic dimension of risk disclosure is perceived. In
fact, it is not a matter of simply disclosing the risks of the
donation but also taking into account other elements related
to the donor, that is, to the recipient of the informative mes-
sage, such as the donor’s real desire and determination to
donate, and his/her psychological condition and level of
knowledge. Donors’ interpretation of and responses to
uncertainty may depend on their personal characteristics
and values and may be affected by the manner in which
uncertainty and risks related to donation are communicated
[102–104] and reported that when initially agreeing to
donate, donors had hardly any information about the proce-
dure and its associated risks. This suggests that the decision
was not the result of a logical process but rather an emotional
reaction. The reactions were towards a terminally ill recipi-
ent, a fear of loss, the desire to save a loved one, or an
outgrowth of family, social, or moral expectations. The
results of studies investigating the accession process to living
kidney donation were similar [105–107]. The same concerns
may arise also in hematopietic stem cells donation. A greater
focus on risk perception by donors is thus needed since, with-
out it, real and full freedom of choice is unlikely.
Even more thorny concerns arise when the proposed
donor is a minor. When children do serve as living donors,
these donations raise serious ethical issues that mainly focus
on an even more careful benefit/burden balance in the per-
spective of avoiding any possible risk to the paediatric donor.
7. Conflict of Interest
It seems opportune to dedicate a number of reflections to the
question of the potential conflict of interest, which may arise
in allo-HSCT practice.
The phenomenology of the possible conflicts of interest is
vast and highly polymorphous, the very concept of “conflict
of interest” not always being clear and univocal [108].
Broadly speaking, there is a conflict of interest when profes-
sional judgement concerning a primary interest (the health
of a patient, for example) tends to be unduly influenced by
a secondary interest (economic gain, personal advantage)
with conscious violations of obligations. More subtle situa-
tions where good judgement may be affected unknowingly
exist [108].
It appears evident that in some cases of medical practice,
the doctor-patient relationship may be influenced by the fig-
ure of a third person. In these cases, conflicts of interest are
more likely.
Such is the case of allo-HSC transplantation in which
there are two patients: the donor (who, in general, has no
medical benefits from the donation) and the potential recip-
ient (for whom the procedure may be lifesaving). The issue is
even more complex when the donors and the recipients are
relatives, often siblings [109].
When a single physician has the responsibility for both
donor selection and recipient care, his/her sound judgement
may be unknowingly affected. In donation-transplantation
relationships, undue involuntary influences on the physician
may occur and the interest of one party (recipient or donor)
may be perceived by the physician to be stronger. It appears
inevitable that the judgement of the physician who manage
the donor could be “vitiated” by the influence of the suffering,
the illness, and the impending death of the recipient. For this
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reason, both the National Marrow Donor Program (NMDP)
and theWMDA [110] state that the medical evaluation of the
unrelated donor must be performed by a physician who is
not a member of the transplantation team caring for the
patient.
In real practice, however, medical management of recip-
ients and their related donors by the same provider is com-
mon [109–111]. In 2012, a survey of Italian transplant
centres reported a high percentage of cases in which donors
and recipients were cared by the samemember of the medical
team [62]. Similar results have been found in other recent
surveys carried out both in Europe [111] and in the USA
[109] even though the recommended practice is that the
donor and recipient are assessed by different experts.
8. Liability and Insurance
HSCT may be considered a single phenomenon which, from
the standpoint of medical malpractice, may show two faces of
the same coin.
The first concerns potential malpractice claims related to
adverse, undesirable events in the recipients. These may
involve malpractice actions by recipients who may have
developed serious complications (such as life-threatening
infections) or death following the transplantation. Further-
more, clinical failure may be alleged, since, despite the fact
that HSC transplantation can be curative for many disorders
and malignancies yet for many conditions, success rates
remain frustratingly low and morbidity and mortality remain
unacceptably high. Physicians are required to follow a known
pattern of therapy and treatment on a sick individual. Treat-
ment is explained to the patient (or to his/her legal guardian)
before it is administered, and the patient agrees (or not),
knowing (as far as possible) the predictable anticipated
results as well as the possible complications. Liability is
imposed and remedies set for failure. In the case of litigation,
courts are called to judge the physicians responsible for the
cure of the transplant recipients following the established
principles and legal requirements of medical liability [112]:
a breach of duty on the part of the physicians to provide ade-
quate care and treatment to the patient, a deviation from the
standards of the profession, a causal relationship between
such breach of duty and injury to the patient, and the exis-
tence of damages that flow from the injury. The remedy of
insurance schemes is intended to provide compensation
when injury or death results from lack of skill or negligence
and, finally, in accordance with national legislations, even
from an inadequacy of informed consent.
The second issue concerns malpractice claim alleged by
hematopoietic stem cells donors. It is noteworthy that it has
been reported that the majority of the donors of bone mar-
row and peripheral blood stem cells are satisfied with their
donation and complain only of transient minor side effects.
Only few donors suffer more severely and/or for more pro-
tracted negative events. Serious complications and side
effects, or death, due to bone marrow or peripheral blood
stem cell donation are extremely rare [113]. As in the case
of stem cells recipients, potential malpractice allegations
may be related to any adverse events or physical harm (for
example, due to drug administration in peripheral blood
stem cells donors and to anaesthesia in bone marrow donors)
caused by any of the events of the donation chain, including
those prior to donation. Furthermore, because of the pecu-
liarity of the act of donation, the issue of autonomy and con-
sent by donors may assume even greater importance in
malpractice and doctors’ negligence in failing to fully explain
to donors that the risks involved with the donation at the
time of consent may attract claim allegations.
Since the primary responsibility of donor registries and
transplantation centres is to protect the donors and ensure
their safety, in the case of any adverse event related to any
phase of the donation process, the registry or the centre
should offer benefits to all stem cell donors. These benefits
might be provided through insurance coverage [114]. Mov-
ing from the first guidelines issued by WMDA in 1994
[115], the assumption that life and disability insurance
should be obtained for each donor before the harvest proce-
dure is indispensable. In the latest guidelines [116], the gen-
eral rule expressly dealing with insurance remedy is
strongly reaffirmed: “The registry must assume responsibility
and establish procedures for all donor medical expenses
including the pre-collection physical examination, the collec-
tion procedure and all post-collection medical expenses that
are directly related to the donation. No volunteer donor
should assume financial liability for any portion of the follow
up testing and/or HPC procurement process. The registry is
responsible for all reasonable expenses incurred by the
donor. The registry, or its designee, should offer disability
and death benefits to all volunteer donors. The registry
should maintain liability insurance.”
As part of the communication process, donors have to be
informed of the existing liability insurance scheme of the reg-
istry or centre, focusing on its content and limitations. Any
limitation in insurance must be clearly explained to the
donor [113].
Finally, since the international exchange of stem cells and
the percentage of products crossing international borders are
more and more increasing [117], international standards
regarding the coverage and level of compensation of insur-
ance are mandatory [113].
9. Conclusions
HSCT is a modern day success story, an irreplaceable thera-
peutic opportunity, and a factual relevance unimaginable
until some years ago. For recipients, both adults and children,
HSCT may represent the only plausible therapeutic solution.
For the donor and their relatives, something good, especially
from a psychological point of view, may emerge from dona-
tion. For the medical profession and for the society as a
whole, there is an opportunity to bring about a cure for
otherwise intractable diseases. However, even on the aware-
ness of the deep significance and therapeutic importance of
HSCT, the challenges are great. HSCT imposes operative
cautions so that the entire donation/transplantation proce-
dure is safe for both donors and recipients. Furthermore,
HSCT carries with it significant clinical, moral, and ethical
concerns, mostly when donors are minor and the donation
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process occurs within the familial context. The saviour sib-
ling issue is a clear example of the potential complexity and
psychological burden of decision-making process in this
peculiar context.
In several diseases, HSCT may be the best solution in
terms of survival and quality of life; however, it is not without
problems. The ethical and juridical importance of consent
cannot be neglected. The act of donation is likely to be dic-
tated by altruism or great solidarity; the concern is that, in
some situations (i.e., when donors are minor and the dona-
tion act is within the family context), situations that could
force on donors (i.e. the possibility of psychological pressure
on the donor) can occur, even if at an unconscious level. The
conceptual paradigm of consent lies on the protection of
donors’ autonomy and personal dignity. National and inter-
national efforts must aim at avoiding any kind of coercion,
commercialization, and economic gain in the act of donation.
Finally, HSCT may present significant conflict of interest
to medical staff, which may be less or more perceived when a
single physician has the responsibility for both donor selec-
tion and recipient care. The roller coaster of emotions
involved in these situations can overwhelm the critical,
clinical judgement of the physician.
In light of the previous discussion, the following points
should be stressed: the donation should be excluded when
excessive risks for the donor are reasonable; donors must
receive an accurate information regarding eventual adverse
events and health burden for the donors themselves; a valid,
free, and informed consent, to prove the freedom of an altru-
istic act like the donation, is required; and the recipient’s risks
must be outweighed by the expected benefits. Finally, there is
a strict need of an adequate insurance protection for all the
parties involved in allo-HSCT procedures.
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